Introduction
Pseudomonas aeruginosa is a major opportunistic pathogen responsible for hospital-acquired infections and is notorious for its capacity to develop resistance to multiple classes of β-lactams. Recently, carbapenems have been shown to be the most important and effective therapeutic options against serious infections caused by these pathogens, but resistance to these agents is increasingly reported worldwide [1, 2, 32].
Carbapenem resistance in P. aeruginosa is mainly due to a combination of different factors: low outer membrane permeability, overexpression of the efflux pump MexABOprM, hyperproduction of derepressed AmpC chromosomal β-lactamase, and the presence of transferable resistance determinants, in particular, carbapenem-hydrolyzing enzymes [6, 9, 19, 20]. Carbapenem-hydrolyzing enzymes are divided into two types based on molecular classification: serine enzymes, which are derivatives of class A or D enzymes, and metallo enzymes, which belong to class B [25].
Serine carbapenemases of the Klebsiella pneumoniae carbapenemase (KPC), Guiana extended-spectrum (GES), and oxacilinase (OXA) families have been occasionally reported in this species in certain parts of the world, whereas metallo-β-lactamases (MBLs), particularly Verona imipenemase (VIM), and IMP (active against imipenem) types, are the most widespread and have been reported globally [4, 12, 26, 29].
In addition to carbapenem-hydrolyzing enzymes, another important mechanism of resistance to β-lactams in P. aeruginosa is the production of chromosomal AmpC β-lactamases, which can be induced or derepressed to confer high-level penicillin and cephalosporin resistance [27]. Inducible AmpC can be upregulated by subinhibitory concentrations of certain β-lactams. Furthermore, mutations can occur in the regulatory components of AmpC, leading to stable hyperproduction of AmpC with concomitant high-level resistance to many classes of β-lactams [21, 24]. Several chromosomally mediated Pseudomonas-derived cephalosporinases (PDCs) with extended-spectrum cephalosporinase activities have been reported among P. aeruginosa [23]. There are several reports on the prevalence of MBL genes and molecular epidemiology in carbapenemresistant P. aeruginosa isolates from Korea, but the contribution of other mechanisms to carbapenem resistance such as class A and D β-lactamase and PDC genes is unknown.
The aim of this study was to determine the diversity and frequency of β-lactamases and characterize chromosomal AmpC β-lactamase in carbapenem-resistant P. aeruginosa isolates obtained from a tertiary hospital in Korea during a 4-year period. In addition, we investigated the epidemiological relationship and potential correlations between genetic characteristics and resistance to carbapenems.
Materials and Methods
Bacterial Isolation and Identification
A total of 61 consecutive and non-duplicated carbapenemresistant P. aeruginosa isolates were collected from patients in a tertiary hospital in Daejeon, Korea, from January 2011 to June 2014. The isolates were identified with the Vitek 2 automated ID system (BioMérieux, Hazelwood, MO, USA), and carbapenemresistant P. aeruginosa isolates were selected based on resistance to imipenem and meropenem.
Antimicrobial Susceptibility Testing
In the antimicrobial susceptibility tests, the minimum inhibitory concentration (MIC) was determined by using the agar dilution method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [3]. Four antimicrobial agents were tested, including imipenem, meropenem, ceftazidime, and cefepime (Sigma-Aldrich, St. Louis, MO, USA). The interpretation of susceptibility was performed according to the CLSI breakpoints. E. coli ATCC 25922 and P. aeruginosa ATCC 27853 were used as quality control strains.
Multilocus Sequence Typing
Multilocus sequence typing (MLST) was performed according to the methods described on the P. aeruginosa MLST database website (http://pubmlst.org/paeruginosa/). PCR and sequencing were performed for seven housekeeping genes (acsA, aroE, guaA, mutL, nuoD, ppsA, and trpE). The nucleotide sequences of these genes were compared with the sequences submitted to the MLST database to determine the allelic numbers and sequence types (STs).
Identification and Analysis of β-Lactamase Genes and Integrons
PCR assays were performed to amplify the sequence of MBLs, including the blaIMP, blaVIM, blaGIM, blaSPM, blaSIM, blaNDM, blaAIM, blaDIM, and blaFIM genes, as described previously (Table 1) [17, 18]. PCR detection of class A and D β-lactamase genes (blaTEM, blaSHV, blaGES, blaVEB, blaKPC, blaPSE, blaPER, blaCTX-M-1,2,9 group, blaOXA-I,II,III group, blaOXA-23, blaOXA-24, blaOXA-48, blaOXA-51, and blaOXA-58) and class 1, 2, and 3 integrons was also performed as previously described [7, 11, 20, 31]. Sequence analyses were confirmed with the BLAST program at the National Center for Biotechnology Information server (http://www.ncbi.nlm.nih.gov/). The structure of variable regions of integrons was determined by PCR mapping and sequencing.
Table 1.Oligonucleotides used as primers for amplication and sequencing in this study.
Genotypic Detection and Sequencing of Chromosomally Encoded and Plasmid-Mediated ampC Gene
The genotypes of all 61 carbapenem-resistant P. aeruginosa isolates were analyzed for the presence of chromosomal PDC genes and for different families of plasmid-mediated ampC genes by multiplex PCR as described previously [15, 23]. Amplified PCR products were purified and sequenced; the results of DNA sequencing were compared with known β-lactamase gene sequences using the BLAST program.
Statistical Analysis
The data were analyzed using SPSS ver. 21.0 (SPSS, Chicago, IL, USA) with one-way analysis of variance. The differences were considered statistically significant at p < 0.05.
Results
MLST Analysis of Carbapenem-Resistant P. aeruginosa
Among the 61 carbapenem-resistant P. aeruginosa isolates, the sites of isolation were sputum (29 isolates, 47.5%), urine (22 isolates, 36.1%), blood (4 isolates, 6.6%), wounds (3 isolates, 4.9%), bile (2 isolates, 3.3%), and pus (1 isolate, 1.6%) (Table 2). A total of 61 carbapenem-resistant P. aeruginosa isolates were identified as 17 different STs by MLST experiments. ST235 (30 isolates, 49.2%) was the most frequently detected clone. According to frequency, five other detected STs were ST245 (5 isolates, 8.2%), ST654 (5 isolates, 8.2%), ST357 (4 isolates, 6.6%), ST111 (3 isolates, 4.9%), and ST257 (3 isolates, 4.9%). The remaining 11 STs (ST179, ST195, ST244, ST267, ST274, ST589, ST645, ST708, ST1062, ST1455, and ST1663) were each represented by one isolate (1.6%).
Table 2.Abbreviations: ST, sequence type.
Prevalence of β-Lactamases
Of the 61 isolates, 10 isolates (16.4%) harbored OXA-type and 2 (3.3%) harbored Pseudomonas-specific enzyme (PSE)-type enzyme (Table 3). Of the OXA β-lactamases,OXA-10was the most prevalent, followed by OXA-1 and OXA-2. Fourteen isolates (23.0%) harbored two different β-lactamases, and 12 isolates (19.7%) harbored three enzymes. Of these, MBL genes were identified in 25 isolates (41.0%) harboring blaOXA-1. Two MBL genes, blaIMP-6 and blaVIM-2, were identified in 22 (36.1%) and 3 isolates (4.9%), respectively. All 22 isolates carrying the blaIMP-6 gene belonged to ST235 and three isolates carrying the blaVIM-2 gene belonged to ST357.
Table 3.revalence of Ambler class A, B, and D β-lactamases in 61 carbapenem-resistant Pseudomonas aeruginosa isolates.
Structure of Class 1 Integrons
Class 1 integrons were detected in 36 (59.0%) of the 61 carbapenem-resistant P. aeruginosa isolates and no class 2 or 3 integrons were found. The gene cassettes found in this study were divided into six types (Type A, B, C, D, E, and F) according to the cassette composition (Table 4). Type A (4.0 kb), obtained in 18 isolates, carried the aadB-cmlA-blaOXA-10-aadA1 gene cassette. Eleven isolates of type B (5.5 kb) belonged to ST235 and carried blaIMP-6 -qac-aacA4-blaOXA-10- aadA2. Type C (1.8 kb), found in two isolates, carried aacA4-blaOXA-2-orfD, and type D (1.2 kb) had aadA6-orfD (2 isolates). Two isolates contained type E (1.0 kb) carrying the aadA4 gene cassette. Type F (2.5 kb) was detected in only one isolate and carried aadA4-blaOXA-10- aadA2.
Table 4.Schematic representation of gene cassette structures located in the class 1 integron isolated from 61 carbapenem-resistant Pseudomonas aeruginosa isolates.
Identification of AmpC Variants
On performing PCR for the presence of chromosomal ampC gene, all 61 isolates of P. aeruginosa harbored PDC gene while the plasmid-mediated ampC gene was not present. Sequencing analysis of the PCR product of the chromosomal ampC gene revealed that 61 isolates obtained six variants (PDC-1, PDC-2, PDC-3, PDC-5, PDC-7, and PDC-8) (Table 5).
Table 5.Abbreviations: N, number of isolates; CAZ, ceftazidime; CFP, cefepime; IPM, imipenem; MEM, meropenem.
The most frequent variant was PDC-2 (30 isolates, 49.2%) and PDC-3 was the second most frequently detected variant (10 isolates, 16.4%). Thirty isolates producing PDC-2 were highly resistant to ceftazidime (MIC50 = 256 µg/ml) and cefepime (MIC50 = 256 µg/ml). Meanwhile, the remaining 31 isolates showed full or intermediate susceptibility, with the ceftazidime MIC50 ranging from 8 to 16 µg/ml. Additionally, 25 isolates harboring MBL genes were highly resistant to ceftazidime (MIC range 64 to >256 µg/ml), cefepime (MIC range 64 to >256 µg/ml), imipenem (MIC range >256 µg/ml), and meropenem (MIC range >256 µg/ml) (Table 6). In contrast, 36 isolates that did not contain MBL genes showed relatively low resistance, with MICs ranging from 2 to 128 µg/ml for ceftazidime, 2 to >256 µg/ml for cefepime, 8 to >256 µg/ml for imipenem, and 8 to >256 µg/ml for meropenem.
Table 6.Abbreviations: N, number of isolates; CAZ, ceftazidime; CFP, cefepime; IPM, imipenem; MEM, meropenem
Discussion
Resistance to β-lactams (particularly carbapenem and cephalosporin) in P. aeruginosa has been increasingly reported worldwide, and this is also the case in Korea. According to previous Korean National Surveillance Antimicrobial Resistance (KONSAR) studies, from 2005 to 2011, resistance rates of P. aeruginosa to imipenem increased from 19% to 26%, and to ceftazidime increased from 19% to 23% [33]. This study analyzed various genes of P. aeruginosa isolates that are responsible for resistance to carbapenems. Class D OXA β-lactamases were more frequently detected than class A in P. aeruginosa (16.4% versus 3.3%). In particular,OXA-10was only observed in ST235 isolates (19 isolates), and was accompanied by blaIMP-6 in 12 isolates (63.2%). Similarly, a previous study found that 35 (60.3%) of 58 OXA-10-producing isolates harbored blaIMP-6 and/or blaVIM-2, and belonged to only ST235 [1]. In addition, 25 (41.0%) carbapenem-resistant P. aeruginosa isolates were MBL producers.
Compared with a previous study, the rates of MBL production showed a 2.5-fold increase from 16.2% in 2008– 2012 to 41.0% in 2011–2014 among carbapenem-resistant P. aeruginosa isolates [2]. Among the 22 ST235 IMP-6-producing isolates, 11 isolates (50.0%) shared an identical class 1 integron with a gene cassette array (blaIMP-6-qac-aacA4-blaOXA-1-aadA1) between the 5’ and 3’ conserved sequence. The blaVIM-2gene was identified in three isolates of ST357.
Mechanisms of drug resistance in AmpC β-lactamase can either be chromosomally or plasmid-mediated. The majority of AmpC β-lactamases are chromosomally mediated and are found in Serratia, Pseudomonas, Acinetobacter, Citrobacter, and Enterbacter spp. Chromosomally mediated resistance is due to mutation(s) in the bacterial DNA, and such genes are not easily transferable to other bacterial species [5, 8]. In the present study, six variants of the chromosomally mediated ampC enzyme PDC were identified in all 61 carbapenem-resistant P. aeruginosa isolates. The most frequent AmpC-type variant was PDC-2, containing the substitutions G27D, A97V, T105A, and V205L. Substitutions in this region have been previously linked to the broadening of the enzyme’s hydrolytic spectrum, facilitating the degradation of compounds such as ceftazidime [10, 22]. In our study, 30 isolates harboring PDC-2 exhibited high levels of resistance to ceftazidime (MIC50 = 256 µg/ml) and cefepime (MIC50 = 256 µg/ml). Additionally, of the 30 isolates, 20 (66.7%) belonged to ST235 and most of the ST235 isolates were recovered from urine (14 isolates, 70%). Another study from France reported 10 variants of a PDC (PDC 1-10) gene, in which several variants showed reduced susceptibility to ceftazidime, cefepime, and imipenem [23, 28].
Plasmid-mediated AmpC β-lactamases can spread laterally, making them transferable to other bacteria. Therefore, they are frequently seen in many bacterial species such as E. coli, K. pneumonia, Salmonella spp., Citrobacter freundii, Enterobacter aerogenes, and Proteus mirabilis [5, 16]. In this study, we were unable to detect plasmid-mediated ampC genes, which is consistent with a previous study by Wang et al. [30], who reported that no plasmid-mediated ampC genes were detected among 258 carbapenem-resistant P. aeruginosa isolates.
Of all the PDC variants, 25 isolates harboring MBL genes showed high levels of cephalosporin (MIC range for ceftazidime and cefepime, 64 to >256 µg/ml) and carbapenem (MIC range for imipenem and meropenem, >256 µg/ml) resistance, whereas 36 isolates that did not harbor MBL genes revealed relatively low-level resistance (MIC range for ceftazidime, 2–128 µg/ml; cefepime, 2 to >256 µg/ml; imipenem and meropenem, 8 to >256 µg/ml). These results highlight the importance of MBL genes in cephalosporin and carbapenem resistance in P. aeruginosa (ceftazidime, cefepime, and meropenem, p < 0.001; imipenem, p = 0.003).
Similarly, Bae et al. [1] reported that production of IMP-6 and VIM-2 MBLs is the main mechanism for acquiring resistance to ceftazidime and carbapenems in P. aeruginosa isolates. In addition, Neyestanaki et al. [11] found that the production of MBLs and AmpC β-lactamases was the major emerging mechanism of resistance to carbapenem among P. aeruginosa isolates in Teharan, Iran. Similarly, combinations of various β-lactamases have recently been reported in studies from India, Brazil, Italy, and Argentina [13, 14].
In conclusion, the coexistence of MBLs and AmpC β-lactamases suggests that these may be important contributing factors for cephalosporin and carbapenem resistance. Therefore, efficient detection and intervention to control drug resistance are necessary to prevent the emergence of P. aeruginosa possessing this combination of β-lactamases.
References
- Bae IK, Suh B, Jeong SH, Wang KK, Kim YR, Yong D, et al. 2014. Molecular epidemiology of Pseudomonas aeruginosa clinical isolates from Korea producing β-lactamases with extended-spectrum activity. Diagn. Microbiol. Infect. Dis. 79: 373-377. https://doi.org/10.1016/j.diagmicrobio.2014.03.007
- Cho HH, Kwon KC, Sung JY, Koo SH. 2013. Prevalence and genetic analysis of multidrug-resistant Pseudomonas aeruginosa ST235 isolated from a hospital in Korea, 2008-2012. Ann. Clin. Lab. Sci. 43: 414-419.
- Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: twentysecond informational supplement. M100-S22. CLSI, Wayne, Pennsylavania.
- Cornaglia G, Giamarellou H, Rossolini GM. 2011. Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect. Dis. 11: 381-393. https://doi.org/10.1016/S1473-3099(11)70056-1
- Grover N, Sahni AK, Bhattacharya S. 2013. Therapeutic challenges of ESBLS and AmpC β-lactamase producers in a tertiary care center. Med. J. Armed Forces India 69: 4-10. https://doi.org/10.1016/j.mjafi.2012.02.001
- Huang YT, Chang SC, Lauderdale TL, Yang AJ, Wang JT. 2007. Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa carrying metallo-beta-lactamase genes in Taiwan. Diagn. Microbiol. Infect. Dis. 59: 211-216. https://doi.org/10.1016/j.diagmicrobio.2007.01.009
- Hu LF, Chang X, Ye Y, Wang ZX, Shao YB, Shi W, et al. 2011. Stenotrophomonas maltophilia resistance to trimethoprim/ sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int. J. Antimicrob. Agents 37: 230-234. https://doi.org/10.1016/j.ijantimicag.2010.10.025
- Jacoby GA. 2009. AmpC β-lactamases. Clin. Microbiol. Rev. 22: 161-182. https://doi.org/10.1128/CMR.00036-08
- Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterialresistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22: 582-610. https://doi.org/10.1128/CMR.00040-09
- Mammeri H, Nordmann P. 2007. Extended-spectrum cephalosporinases in Enterobacteriaceae. Anti-Infect. Agents Med. 6: 71-82. https://doi.org/10.2174/187152107779314133
- Neyestanaki DK, Mirsalehian A, Rezagholizadeh F, Jabalameli F, Taherikalani M, Emaneini M. 2014. Determination of extended spectrum β-lactamases, metallo-β-lactamases and AmpC-β-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients. Burns 40: 1556-1561. https://doi.org/10.1016/j.burns.2014.02.010
- Pasteran F, Faccone D, Gomez S, De Bunder S, Spinelli F, Rapoport M, et al. 2012. Detection of an international multiresistant clone belonging to sequence type 654 involved in the dissemination of KPC-producing Pseudomonas aeruginosa in Argentina. J. Antimicrob. Chemother. 67: 1291-1293. https://doi.org/10.1093/jac/dks032
- Pasteran F, Faccone D, Petroni A, Rapoport M, Galas M, Vázquez M, et al. 2005. Novel variant (bla(VIM-11)) of the metallo-{β}-lactamase bla(VIM) family in a GES-1 extendedspectrum-{β}-lactamase-producing Pseudomonas aeruginosa clinical isolate in Argentina. Antimicrob. Agents Chemother. 49: 474-475. https://doi.org/10.1128/AAC.49.1.474-475.2005
- Pellegrino FL, Teixeira LM, Carvalho Md Mda G, Aranha Nouér S, Pinto De Oliveira M, Mello Sampaio JL, et al. 2002. Occurrence of a multidrug-resistant Pseudomonas aeruginosa clone in different hospitals in Rio de Janeiro, Brazil. J. Clin. Microbiol. 40: 2420-2424. https://doi.org/10.1128/JCM.40.7.2420-2424.2002
- Pérez-Pérez FJ, Hanson ND. 2002. Detection of plasmidmediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40: 2153-2162. https://doi.org/10.1128/JCM.40.6.2153-2162.2002
- Philippon A, Arlet G, Jacoby GA. 2002. Plasmid-determined AmpC-type beta-lactamases. Antimicrob. Agents Chemother. 46: 1-11. https://doi.org/10.1128/AAC.46.1.1-11.2002
- Poirel L, Walsh TR, Cuvillier V, Nordmann P. 2011. Multiplex PCR for detection of acquired carbapenemase genes. Diagn. Microbiol. Infect. Dis. 70: 119-123. https://doi.org/10.1016/j.diagmicrobio.2010.12.002
- Pollini S, Maradei S, Pecile P, Olivo G, Luzzaro F, Docquier JD, et al. 2013. FIM-1, a new acquired metallo-β-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy. Antimicrob. Agents Chemother. 57: 410-416. https://doi.org/10.1128/AAC.01953-12
- Poole K. 2011. Pseudomonas aeruginosa: resistance to the max. Front Microbiol. 2: 65. https://doi.org/10.3389/fmicb.2011.00065
- Qing Y, Cao KY, Fang ZL, Huang YM, Zhang XF, Tian GB, et al. 2014. Outbreak of PER-1 and diversity of β-lactamases among ceftazidime-resistant Pseudomonas aeruginosa clinical isolates. J. Med. Microbiol. 63: 386-392. https://doi.org/10.1099/jmm.0.069427-0
- Quale J, Bratu S, Gupta J, Landman D. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50: 1633-1641. https://doi.org/10.1128/AAC.50.5.1633-1641.2006
- Raimondi A, Sisto F, Nikaido H. 2001. Mutation in Serratia marcescens AmpC β-lactamase producing high-level resistance to ceftazidime and cefpirome. Antimicrob. Agents Chemother. 45: 2331-2339. https://doi.org/10.1128/AAC.45.8.2331-2339.2001
- Rodríguez-Martínez JM, Poirel L, Nordmann P. 2009. Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53: 1766-1771. https://doi.org/10.1128/AAC.01410-08
- Rodríguez-Martínez JM, Poirel L, Nordmann P. 2009. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53: 4783-4788. https://doi.org/10.1128/AAC.00574-09
- Sanbongi Y, Shimizu A, Suzuki T, Nagaso H, Ida T, Maebashi K, et al. 2009. Classification of OprD sequence and correlation with antimicrobial activity of carbapenem agents in Pseudomonas aeruginosa clinical isolates collected in Japan. Microbiol. Immunol. 53: 361-367. https://doi.org/10.1111/j.1348-0421.2009.00137.x
- Sevillano E, Gallego L, García-Lobo JM. 2009. First detection of the OXA-40 carbapenemase in P. aeruginosa isolates, located on a plasmid also found in A. baumannii. Pathol. Biol. (Paris) 57: 493-495. https://doi.org/10.1016/j.patbio.2008.05.002
- Tian GB, Adams-Haduch JM, Bogdanovich T, Wang HN, Doi Y. 2011. PME-1, an extended-spectrum β-lactamase identified in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 55: 2710-2713. https://doi.org/10.1128/AAC.01660-10
- Upadhyay S, Mishra S, Sen MR, Banerjee T, Bhattacharjee A. 2013. Co-existence of Pseudomonas-derived cephalosporinase among plasmid encoded CMY-2 harbouring isolates of Pseudomonas aeruginosa in north India. Indian J. Med. Microbiol. 31: 257-260. https://doi.org/10.4103/0255-0857.115629
- Viedma E, Juan C, Acosta J, Zamorano L, Otero JR, Sanz F, et al. 2009. Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum β-lactamases GES-1 and GES-5 in Spain. Antimicrob. Agents Chemother. 53: 4930-4933. https://doi.org/10.1128/AAC.00900-09
- Wang J, Zhou JY, Qu TT, Shen P, Wei ZQ, Yu YS, et al. 2010. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals. Int. J. Antimicrob. Agents 35: 486-491. https://doi.org/10.1016/j.ijantimicag.2009.12.014
- Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents 27: 351-353. https://doi.org/10.1016/j.ijantimicag.2006.01.004
- Wright LL, Turton JF, Livermore DM, Hopkins KL, Woodford N. 2015. Dominance of international ‘high-risk clones’ among metallo-β-lactamase-producing Pseudomonas aeruginosa in the UK. J. Antimicrob. Chemother. 70: 103-110. https://doi.org/10.1093/jac/dku339
- Yong D, Shin HB, Kim YK, Cho J, Lee WG, Ha GY, et al. 2014. Increase in the prevalence of carbapenem-resistant Acinetobacter isolates and ampicillin-resistant non-typhoidal Salmonella species in Korea: a KONSAR study conducted in 2011. Infect. Chemother. 46: 84-93. https://doi.org/10.3947/ic.2014.46.2.84
Cited by
- Microcalorimetry and turbidimetry to investigate the anti-bacterial activities of five fractions from the leaves of Dracontomelon dao on P. aeruginosa vol.123, pp.3, 2016, https://doi.org/10.1007/s10973-015-4932-2
- Identification and Characterization of Putative Integron-Like Elements of the Heavy-Metal-Hypertolerant Strains of Pseudomonas spp. vol.26, pp.11, 2015, https://doi.org/10.4014/jmb.1605.05068
- Antimicrobial resistance in bacterial pathogens among hospitalized children with community acquired lower respiratory tract infections in Dongguan, China (2011–2016) vol.17, pp.None, 2017, https://doi.org/10.1186/s12879-017-2710-4
- In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa vol.19, pp.None, 2015, https://doi.org/10.1186/s12866-019-1522-7
- Propolis Extract: A Possible Antiseptic Oral Care against Multidrug-Resistant Non-Fermenting Bacteria Isolated from Non-Ventilator Hospital-Acquired Pneumonia vol.14, pp.1, 2015, https://doi.org/10.22207/jpam.14.1.13
- Antimicrobial Resistance and Genomic Characterization of Six New Sequence Types in Multidrug-Resistant Pseudomonas aeruginosa Clinical Isolates from Pakistan vol.10, pp.11, 2015, https://doi.org/10.3390/antibiotics10111386
- Genome analysis of alginate synthesizing Pseudomonas aeruginosa strain SW1 isolated from degraded seaweeds vol.114, pp.12, 2015, https://doi.org/10.1007/s10482-021-01673-w